59 related articles for article (PubMed ID: 18272304)
1. Application and limitation of inhibitors in drug-transporter interactions studies.
Wang Q; Strab R; Kardos P; Ferguson C; Li J; Owen A; Hidalgo IJ
Int J Pharm; 2008 May; 356(1-2):12-8. PubMed ID: 18272304
[TBL] [Abstract][Full Text] [Related]
2. Danofloxacin-mesylate is a substrate for ATP-dependent efflux transporters.
Schrickx JA; Fink-Gremmels J
Br J Pharmacol; 2007 Feb; 150(4):463-9. PubMed ID: 17211460
[TBL] [Abstract][Full Text] [Related]
3. Montelukast is a potent and durable inhibitor of multidrug resistance protein 2-mediated efflux of taxol and saquinavir.
Roy U; Chakravarty G; Honer Zu Bentrup K; Mondal D
Biol Pharm Bull; 2009 Dec; 32(12):2002-9. PubMed ID: 19952419
[TBL] [Abstract][Full Text] [Related]
4. Characterization of the intestinal absorption of morroniside from Cornus officinalis Sieb. et Zucc via a Caco-2 cell monolayer model.
Xu R; Zhu H; Hu L; Yu B; Zhan X; Yuan Y; Zhou P
PLoS One; 2020; 15(5):e0227844. PubMed ID: 32470043
[TBL] [Abstract][Full Text] [Related]
5. A systems framework for investigating the roles of multiple transporters and their impact on drug resistance.
di San Germano M; Krishnan J
Integr Biol (Camb); 2024 Jan; 16():. PubMed ID: 38537223
[TBL] [Abstract][Full Text] [Related]
6. Inhibitory effect of clemastine on P-glycoprotein expression and function: an in vitro and in situ study.
Abbasi MM; Valizadeh H; Hamishekar H; Mohammadnejad L; Zakeri-Milani P
Iran J Basic Med Sci; 2016 Apr; 19(4):423-9. PubMed ID: 27279987
[TBL] [Abstract][Full Text] [Related]
7. Effects of Aqueous Boundary Layers and Paracellular Transport on the Efflux Ratio as a Measure of Active Transport Across Cell Layers.
Kotze S; Ebert A; Goss KU
Pharmaceutics; 2024 Jan; 16(1):. PubMed ID: 38276501
[TBL] [Abstract][Full Text] [Related]
8. Differential selectivity of efflux transporter inhibitors in Caco-2 and MDCK-MDR1 monolayers: a strategy to assess the interaction of a new chemical entity with P-gp, BCRP, and MRP2.
Mease K; Sane R; Podila L; Taub ME
J Pharm Sci; 2012 May; 101(5):1888-97. PubMed ID: 22359351
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of Encequidar as An Intestinal P-gp and BCRP Specific Inhibitor to Assess the Role of Intestinal P-gp and BCRP in Drug-Drug Interactions.
Chu J; Panfen E; Wang L; Marino A; Chen XQ; Fancher RM; Landage R; Patil O; Desai SD; Shah D; Xue Y; Sinz M; Shen H
Pharm Res; 2023 Nov; 40(11):2567-2584. PubMed ID: 37523014
[TBL] [Abstract][Full Text] [Related]
10. Exploration of the Plausible Mechanism of Ethambutol Induced Ocular Toxicity by Using Proteomics Informed Physiologically Based Pharmacokinetic (PBPK) Modeling.
Balhara A; Ladumor MK; Nankar RP; Syed SD; Giri S; Prasad B; Singh S
Pharm Res; 2022 Apr; 39(4):677-689. PubMed ID: 35301670
[TBL] [Abstract][Full Text] [Related]
11. Functional characterization of Clonorchis sinensis sodium-bile acid co-transporter (CsSBAT) as a steroid sulfate transporter.
Jung H; Won JY; Park YK; Han JH; Cha SH
Parasitol Res; 2022 Jan; 121(1):217-224. PubMed ID: 34825261
[TBL] [Abstract][Full Text] [Related]
12. Study on mechanism of low bioavailability of black tea theaflavins by using Caco-2 cell monolayer.
Qu F; Ai Z; Liu S; Zhang H; Chen Y; Wang Y; Ni D
Drug Deliv; 2021 Dec; 28(1):1737-1747. PubMed ID: 34463173
[TBL] [Abstract][Full Text] [Related]
13. Contribution of Uptake and Efflux Transporters to Oral Pharmacokinetics of Furosemide.
Chapa R; Li CY; Basit A; Thakur A; Ladumor MK; Sharma S; Singh S; Selen A; Prasad B
ACS Omega; 2020 Dec; 5(51):32939-32950. PubMed ID: 33403255
[TBL] [Abstract][Full Text] [Related]
14. Applicability of free drug hypothesis to drugs with good membrane permeability that are not efflux transporter substrates: A microdialysis study in rats.
Chen C; Zhou H; Guan C; Zhang H; Li Y; Jiang X; Dong Z; Tao Y; Du J; Wang S; Zhang T; Du N; Guo J; Wu Y; Song Z; Luan H; Wang Y; Du H; Zhang S; Li C; Chang H; Wang T
Pharmacol Res Perspect; 2020 Apr; 8(2):e00575. PubMed ID: 32266794
[TBL] [Abstract][Full Text] [Related]
15. The inhibitory effects of mitragynine on P-glycoprotein in vitro.
Rusli N; Amanah A; Kaur G; Adenan MI; Sulaiman SF; Wahab HA; Tan ML
Naunyn Schmiedebergs Arch Pharmacol; 2019 Apr; 392(4):481-496. PubMed ID: 30604191
[TBL] [Abstract][Full Text] [Related]
16. Different structures of berberine and five other protoberberine alkaloids that affect P-glycoprotein-mediated efflux capacity.
Zhang YT; Yu YQ; Yan XX; Wang WJ; Tian XT; Wang L; Zhu WL; Gong LK; Pan GY
Acta Pharmacol Sin; 2019 Jan; 40(1):133-142. PubMed ID: 30442987
[TBL] [Abstract][Full Text] [Related]
17. Experimental Evaluation of the Transport Mechanisms of PoIFN-α in Caco-2 Cells.
Liu X; Zheng S; Qin Y; Ding W; Tu Y; Chen X; Wu Y; Yanhua L; Cai X
Front Pharmacol; 2017; 8():781. PubMed ID: 29163167
[TBL] [Abstract][Full Text] [Related]
18. In vitro moxifloxacin drug interaction with chemotherapeutics: implications for retinoblastoma management.
Barot M; Gokulgandhi MR; Pal D; Mitra AK
Exp Eye Res; 2014 Jan; 118():61-71. PubMed ID: 24157270
[TBL] [Abstract][Full Text] [Related]
19. Compartmental models for apical efflux by P-glycoprotein--part 1: evaluation of model complexity.
Nagar S; Tucker J; Weiskircher EA; Bhoopathy S; Hidalgo IJ; Korzekwa K
Pharm Res; 2014 Feb; 31(2):347-59. PubMed ID: 24019023
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
